One: The patient has been exposed to a significant amount of toxins and the body cannot replace the used-up GSH quickly enough
This framing ignores emerging evidence that GLP-1s reduce cardiovascular events and mortality in people with obesity, not just glucose management
The core peptide should still contain the same 15 residues in the same order
This combination of increased usage and expanded state coverage has increased Medicaid spending on GLP-1s for obesity to more than $500 million in October 2024 alone, with total expenditures reaching $3.5 billion over the past 12 months
Professor Paul Clayton PhD, who is a clinical pharmacologist, preventative aging expert, and LYMA Director of Science shares: ActivAMP is the first of a new class of natural compounds called 'exercise mimetics'
At the higher end, you are at maintenance doses from a premium clinic with full medical oversight